A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer (NCT05800665)
A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.
Who can join: Review the eligibility criteria below.
Location: HonorHealth — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- HonorHealth — Scottsdale, Arizona
- Yale Cancer Center — New Haven, Connecticut
- Sarah Cannon Research Institute @ Florida Cancer — Orlando, Florida
- University of Illinois Hospital & Health Sciences System — Chicago, Illinois
- SCRI Oncology Partners — Nashville, Texas
- St Vincent's Hospital Sydney — Darlinghurst, New South Wales
- Macquarie University Hospital — New South Wales, New South Wales
- Monash Health Monash Medical Centre — Clayton, Victoria
- Austin Hospital — Heidelberg, Victoria
- British Columbia Cancer Agency — Vancouver, British Columbia
- Princess Margaret Hospital — Toronto, Ontario
- Gustave Roussy — Villejuif, Val-de-Marne
- Centre Léon Bérard — Lyon,
- Institut Paoli Calmettes — Marseille,
- Seoul National University Hospital — Seoul,
- Severance Hospital Yonsei University Health System - PPDS — Seoul,
- Asan Medical Center - PPDS — Seoul,
- Samsung Medical Center - PPDS — Seoul,
- Clinica Universidad de Navarra — Pamplona, Navarre
- Hospital Universitario Vall d'Hebron - PPDS — Barcelona,
- Clinica Universidad de Navarra-Madrid — Madrid,
- Hospital Clinico San Carlos — Madrid,
- Cambridge Clinical Research Centre — Cambridge,
- Leicester Royal Infirmary — Leicester,
- The Christie — Manchester,
📞 Contact the Study Coordinator
Phone: (888) 662-6728
Email: global-roche-genentech-trials@gene.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Prostate Cancer
- PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer. — Houston, Texas
- Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer — Toronto, Ontario
- A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer — Scottsdale, Arizona
- Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT — Boston, Massachusetts
Explore by condition: All Advanced Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.